- Home
- UNCY
as 11-15-2024 4:00pm EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LOS ALTOS |
| Market Cap: | 31.9M | IPO Year: | 2021 |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $1.82 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | -29.02% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Unicycive Therapeutics Inc. News
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
MT Newswires
6 days ago
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
GlobeNewswire
6 days ago
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire
20 days ago
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire
a month ago
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
Clinical Trials Arena
a month ago
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
GlobeNewswire
a month ago
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
GuruFocus.com
a month ago
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc
Compare UNCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UNCY Unicycive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.